Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Predicting treatment response for aggression in schizophrenia is challenging.
• Executive function deficits are common in schizophrenia and may influence treatment outcomes.
• Limited understanding exists regarding how executive function interacts with different antipsychotic medications for aggression management.

Purpose of the Study:

• To investigate if executive function predicts treatment outcomes for aggressive behavior in patients with schizophrenia or schizoaffective disorder.
• To determine if this predictive relationship varies across different antipsychotic medication groups (clozapine, olanzapine, haloperidol).

Main Methods:

• A 12-week, double-blind, randomized trial involving 99 aggressive inpatients diagnosed with schizophrenia or schizoaffective disorder.
• Participants were assigned to clozapine, olanzapine, or haloperidol and underwent executive function testing.
• Aggression was measured using the Modified Overt Aggression Scale (MOAS); psychopathology and side effects were also assessed.

Main Results:

• Poor executive function was associated with higher aggression levels across all three medication groups.
• A significant interaction was observed, with clozapine demonstrating anti-aggression effects even in patients with executive dysfunction.
• Olanzapine showed particular efficacy in patients without executive dysfunction.

Conclusions:

• Executive function is a significant predictor of anti-aggression treatment response in schizophrenia patients.
• Clozapine offers a viable treatment option for aggression, even in the presence of executive dysfunction.
• Findings support a targeted approach to managing aggression in schizophrenia based on individual executive function profiles.